N-phenylsulfonyl-3,5-bis(arylidene)-4-piperidone derivatives as activation NF-κB inhibitors in hepatic carcinoma cell lines
- 1 July 2018
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 155, 531-544
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (21402010, 21702018)
This publication has 32 references indexed in Scilit:
- Synthesis and biological evaluation of novel coumarin–pyrazoline hybrids endowed with phenylsulfonyl moiety as antitumor agentsEuropean Journal of Medicinal Chemistry, 2013
- Synthesis, structure and luminescence of Co-crystals with hexagonal channels: arranging disposition and π–π interactionsCrystEngComm, 2012
- 3,5-Bis(benzylidene)-1-[4-2-(morpholin-4-yl)ethoxyphenylcarbonyl]-4-piperidone hydrochloride: A lead tumor-specific cytotoxin which induces apoptosis and autophagyBioorganic & Medicinal Chemistry Letters, 2010
- Cancer-related inflammationNature, 2008
- Inflammation and Cancer: A Double-Edged SwordCancer Cell, 2007
- Hepatocellular Carcinoma: Epidemiology and Molecular CarcinogenesisGastroenterology, 2007
- Integrating cell-signalling pathways with NF-κB and IKK functionNature Reviews Molecular Cell Biology, 2007
- Hepatocellular carcinoma pathogenesis: from genes to environmentNature Reviews Cancer, 2006
- Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammationTrends in Biochemical Sciences, 2005
- Solvent Exposed Non-contacting Amino Acids Play a Critical Role in NF-κB/IκBα Complex FormationJournal of Molecular Biology, 2002